Pair Name | Sulforaphane, Everolimus | ||
Phytochemical Name | Sulforaphane (PubChem CID: 5350 ) | ||
Anticancer drug Name | Everolimus (PubChem CID: 6442177 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Sulforaphane, Everolimus | |||
Disease Info | [ICD-11: 2C94] | Bladder cancer | Investigative | |
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Expression | AKT1 | hsa207 | |
Down-regulation | Expression | CCNA2 | hsa890 | |
Down-regulation | Expression | CCNB1 | hsa891 | |
Up-regulation | Phosphorylation | CDK1 | hsa983 | |
Down-regulation | Phosphorylation | CDK2 | hsa1017 | |
Up-regulation | Expression | CDKN2D | hsa1032 | |
Up-regulation | Expression | H3C14 | hsa126961 | |
Up-regulation | Expression | HRH4 | hsa59340 | |
Down-regulation | Expression | PSMD9 | hsa5715 | |
Down-regulation | Phosphorylation | RICTOR | hsa253260 | |
Up-regulation | Phosphorylation | RPTOR | hsa57521 | |
In Vitro Model | RT-112 | Bladder carcinoma | Homo sapiens (Human) | CVCL_1670 |
UM-UC-3 | Bladder carcinoma | Homo sapiens (Human) | CVCL_1783 | |
TCCSUP | Bladder carcinoma | Homo sapiens (Human) | CVCL_1738 | |
Result | The addition of SFN to the long-term everolimus application inhibits resistance development in bladder cancer cells in vitro. Therefore, sulforaphane may hold potential for treating bladder carcinoma in patients with resistance to an mTOR inhibitor. |
No. | Title | Href |
---|---|---|
1 | Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. Int J Mol Sci. 2020 Jun 4;21(11):4026. doi: 10.3390/ijms21114026. | Click |